Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland.

Reich, Oliver

Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland. [electronic resource] - BMC ophthalmology Dec 2017 - 234 p. digital

Publication Type: Journal Article

1471-2415

10.1186/s12886-017-0617-x doi


Adult
Aged
Aged, 80 and over
Angiogenesis Inhibitors--administration & dosage
Female
Health Care Costs--statistics & numerical data
Humans
Intravitreal Injections--economics
Macular Degeneration--drug therapy
Male
Middle Aged
Ranibizumab--administration & dosage
Receptors, Vascular Endothelial Growth Factor--administration & dosage
Recombinant Fusion Proteins--administration & dosage
Retrospective Studies
Switzerland
Young Adult